Form 4 Filing for Ascendis Pharma A/S

Jean Jacques Bienaime, a director at Ascendis Pharma A/S, reported the purchase of 400 ordinary shares on May 26, 2026. The shares were acquired in two transactions. The first transaction involved 200 shares purchased at a weighted average price of $236.235, with individual prices ranging from $235.93 to $236.54. The second transaction also involved 200 shares, acquired at a weighted average price of $239.3675, with individual prices ranging from $239.245 to $239.490. Following these transactions, Mr. Bienaime directly owns 400 shares of Ascendis Pharma A/S. The filing was signed on May 27, 2026, by Michael Wolff Jensen as attorney-in-fact for Jean Jacques Bienaime.